Cronos Therapeutics Limited, a London based biopharmaceutical company, and Cancer Research Technology Limited, the specialist oncology development and commercialisation company owned by Cancer Research UK, today announce that they have entered into an agreement to develop a novel cancer therapy based on Cronos’ GeneICE platform technology.
